Wednesday, January 13, 2010

RNAi Therapeutics Portfolio Update: mdRNA (Sell)

mdRNA announced today updates on results in mice for their liposomally delivered RNAi Therapeutics candidates for solid cancers. They also said to have entered into an "early collaborative effort with a major international pharmaceutical company". While not negative news for sure, both types of news items would appear to make the 75% run-up in shares this morning to be an over-reaction, especially given the one-month window it has to find additional funding. I will therefore take a trading profit at $1.71, and possibly look to re-enter the stock, maybe after an opportunistic financing following today's announcement.

Disclaimer: Investments in RNAi Therapeutics are highly risky and not suited for most people.The purpose of the blog and model portfolio is to convey a sense of the dynamics in the field and is NOT an endorsement for making related investments. I also have financial interests in some of the companies included in the portfolio. I do not, however, have short positions in any of those.


Anonymous said...


Look back to October and the MRNA press releases..This is the same rodent data with a different spin..
What I wanted to see was the primate data and it was not even in the latest release.

Saying they are collaborating again?.Why would a shareholder not expect them to be doing that 100% of the time!

I felt the ALNY news last week was interesting and it got no press.

GS said...

Excellent call Dirk!

They got their financing then.
The terms could have been worse.

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.